The gold standard for noninvasive blood pressure (BP) measurement, the Doppler technique, does not provide systolic blood pressure (SBP) and diastolic blood pressure (DBP) and may limit therapy outcomes. To improve patient care, we tested specifically designed experimental BP ( Continuous-flow (CF) left ventricle assist device (LVAD) therapy, an established treatment modality for advanced heart failure (HF), is experiencing exponential growth because of increased durability and progressive engineering of the pumps.
apy, an established treatment modality for advanced heart failure (HF), is experiencing exponential growth because of increased durability and progressive engineering of the pumps. [1] [2] [3] In non-LVAD populations, the arterial blood pressure (BP) is easily obtained by auscultation or the oscillometric method, but in patients supported by CF LVAD, accurate BP assessment remains challenging because of a reduced pulse pressure (PP). 4 Despite advancements in LVAD technology, a specific, clinically validated LVAD BP monitor is not currently available. Traditional automated oscillometric BP monitors are capable of successfully measuring BP in approximately 55-60% of cases regardless of the measurement accuracy, whereas manual auscultation allows BP assessment in less than 20% of LVAD measurements. 4 Currently, clinical management of patients supported by LVAD relies on a Doppler BP method, which significantly overestimates mean arterial pressure (MAP). 5 Intracranial bleeding, one of the major adverse events of LVAD therapy, is associated with poor BP control. 3, 6 Limited availability of Doppler-derived BP could also compromise adequate therapeutic response and negatively influence clinical outcomes. 7, 8 Conversely, in patients with hypertension, the overestimation of MAP may contribute to antihypertensive drug overdosing with subsequent, impaired renal perfusion and a higher risk of falls caused by underlying orthostatic hypotension.
In response to this clinical need, an experimental, noninvasive, brachial cuff blood pressure (ExpBP) monitor has been developed with algorithms customized for the altered hemodynamics of patients supported by LVAD. Accordingly, we studied the validity, repeatability, and measurement "success rate" of the ExpBP monitor compared with the intraarterial (I-A) BP. Second, we compared the noninvasive LVAD ambulatory "gold standard" Doppler technique to the I-A BP in the same population.
Materials and Methods

Patients
A total of 31 patients with end-stage HF (4 females; age, 63 ± 10 years; body mass index, 28.6 ± 6.0 kg/m 2 ) indicated for durable mechanical cardiac support with an LVAD implanted at Mayo Clinic, Rochester, Minnesota, were included in the study.
Noninvasive Blood Pressure Monitor Designed for Patients With Heart Failure Supported with Continuous-Flow Left Ventricular Assist Devices
The patients' demographic information including medical history, cardiac risk factors, and related blood markers is illustrated in Table 1 with the pump characteristics displayed in Table 2 .
Study Design
The present single-center prospective, nonrandomized study was approved by the Mayo Clinic Institutional Review Board. To achieve the goal of the study, BP was measured in patients supported by a CF LVAD Heart Mate II (HM II; Thoratec Corporation, Pleasanton, CA) or HeartWare (HW Corp., Framingham, MA) device at the intensive care unit, 2.6 ± 3.4 days after device implantation. Blood pressure was assessed in patients in a stable, supine position. The invasive BP was recorded continuously via the critical care monitor, Philips IntelliVue MP 50 (Phillips, Eindhoven, the Netherlands) connected to a 20 Fr I-A catheter placed in the radial artery through disposable pressure transducer TruWave PXMK2064 (Edwards Lifesciences, Irvine, CA). Before each recording, the system was flushed, zeroed, and the transducer was leveled at the phlebostatic axis. 9, 10 For the noninvasive BP assessments, appropriately sized cuffs were chosen with the cuff placed either on the ipsilateral or contralateral arm based on clinical restrictions; however, BP was assessed noninvasively by the ExpBP monitor and the Doppler technique from the same extremity. 11 Doppler Flow Detector, model 811-BTS (Parks Medical Electronics Inc., Aloha, OR) with a calibrated sphygmomanometer, Model Baum Pocket Aneroid (W. A. Baum Co. Inc., Copiague, NY) was used for detecting the Doppler BP as previously described. 4 Blood pressure was assessed in triplicate for each measurement method within 1 minute between measurements, obtaining I-A records from the continuous BP monitoring, followed by a noninvasive measurement using the ExpBP monitor, and finally, Doppler ultrasound.
The Noninvasive BP Measurement System
The prototype of the noninvasive BP measurement system was specifically designed for the LVAD population, consisting of the ExpBP monitor operated via the attached computer. The device was developed on a standard oscillometric principle for noninvasive BP measurement 12 with customized hardware and software to adapt for lower BP pulsatility (see Figure 1 , Supplemental Digital Content, http://links.lww.com/ASAIO/A258). The device automatically measured oscillometric pulsations during cuff deflation at a speed of 2 mm Hg/second and was programmed to generate the most linear cuff deflation course, while minimizing artifacts caused by control valves. A standard pressure sensor (Freescale Semiconductor, type: MPXV5050GP) was used to measure the pressure in the cuff. The pressure signal from the sensor was filtered by an analog first-order low-pass antialiasing filter with a cutoff frequency of 140 Hz. Data were then digitized with a sampling frequency of 400 Hz.
Algorithms for Arterial Pressure Detection
The standard oscillometric BP method was applied to obtain MAP values. 12 In the device, the raw digitized pressure signal with oscillometric pulsations was filtered by a third-order high-pass Bessel filter with a cutoff frequency of 0.4 Hz to remove a slowly varying component of deflating cuff pressure. As a result, the filtered signal contained only the superimposed rapid pressure oscillations (at a range about mm Hg). During the cuff deflation, peak-to-peak oscillation amplitude changes gradually increased, reaching a maximum and then decreasing (Figure 1) . It has been shown that the maximum peak-to-peak amplitude of oscillations occurs when the cuff pressure corresponds to the MAP. [12] [13] [14] [15] The device used a MAP detection algorithm that employed a peak detector to find positive and negative peaks of oscillations based on polynomial fitting ( Figure 1) . 16 At the time of a maximum absolute difference of envelopes, the cuff pressure corresponded to MAP, as described previously. 13, 16 The systolic blood pressure (SBP) and diastolic blood pressure (DBP) were obtained using height-based criteria. 17 The successful measurement was considered when the BP value was displayed for a given measurement attempt. The PP was calculated as the difference between SBP and DPB.
Statistical Analyses
According to the recommendations of American Heart Association for BP assessment, the average of the second and the third measurement was considered as a representative value for the calculation of noninvasive BP measures. 11 For the I-A BP measures, 30 second average values were used. Where appropriate, variables were summarized as mean (standard deviation [SD] ) and frequency (percent) for continuous and categorical measurements, respectively. The Bland-Altman (B-A) plots were constructed for the evaluation of the methods agreement between the ExpBP monitor versus I-A BP and Doppler BP versus I-A, respectively, with the bias of ±95% confidence intervals. Also, mean absolute difference (MAD) and Pearson correlations were used to compare between methods. For the repeatability assessment, MAD between the second and third BP measurement for each pressure (MAP, SBP, DBP, and PP) of a given method was performed with Pearson correlation coefficient calculated between obtained values. In addition, the "measurement success rate" was expressed as a percent of total measurement attempts. Data was analyzed using JMP Pro 10 (SAS Institute, Cary, NC) statistical software package, and B-A plots were carried out in GraphPad Prism version 7.00 (GraphPad Software, La Jolla, CA). Significance was considered present when p < 0.05.
Results
The general overview of results, demonstrating means of BP values from all three methods, is illustrated in Figure 2 . SBP, DBP, and MAP were assessed by using the ExpBP monitor with an additional calculation of the PP, compared with the Doppler technique, which generated only a single BP value. 
Validation Analysis of the Experimental BP Monitor and Doppler Technique Referenced to I-A Pressures
The B-A analyses revealed a closer agreement of methods in the assessment of MAP between the ExpBP monitor and I-A pressure compared with the agreement in the MAP derived by the current gold standard, Doppler technique, and I-A MAP (Figure 3, A and B) . Mean absolute differences between ExpBP monitor MAP versus I-A MAP and Doppler BP versus I-A MAP, respectively, were 3.9 ± 1.1 and 7. The Doppler technique has displayed correlation between the second and the third measurement of r = 0.98 (p < 0.01) with a 1.5 ± 1.1 mm Hg of MAD between measurements, when rigorously performed by a single, trained observer.
Measurement Success Rate
In the CF LVAD population, problems commonly associated with the BP assessment using automated devices lead to remarkably a high number of "error" readings, when no values are provided by the BP monitor. In our study, an original approach was applied, allowing for an independent assessment of SBP and DBP from the ExpBP monitor after MAP was positively determined by the algorithm. This allowed for higher success rates for the MAP and SBP compared with DBP values. The Doppler technique achieved a high success rate in a critical care setting ( Table 3 ). 
Subanalysis of Doppler BP According to the I-A PP
By analyzing the accuracy of Doppler measurements, the data revealed a significant positive relationship between the I-A MAP to Doppler BP difference and the I-A PP (r = 0.55; p < 0.01). Also, this relationship between the I-A MAP and the Doppler BP was significant if calculated for I-A SBP to I-A MAP pressure difference (r = 0.57; p < 0.01; Figure 4, A and B) .
Discussion
In the presented work, we tested the performance of an experimental BP monitor specifically designed to overcome the challenging hemodynamic characteristics of patients supported by CF LVADs. The design allowed for the noninvasive measurement of the MAP, SBP, and DBP in majority of patients supported by CF LVAD at early postimplantation stage using the ExpBP monitor. Acquired BP values were in close agreement to the respective invasive BP values. In addition, the accuracy and reliability of the Doppler technique was tested by a single operator under rigorous conditions.
Performance of the Experimental BP Monitor in Respect to Regulatory Standards for BP Monitors
The narrowest ±95% limit of agreement in the B-A analysis was achieved by comparing the I-A to the ExpBP monitor MAP, followed by DBP and SBP. The unique algorithm used in the ExpBP monitor also allowed for the low bias of 1.2 (4.8) mm Hg (mean [SD]) in the MAP assessment, 0.8 (6.1) mm Hg for the SBP, and 1.9 (5.3) mm Hg for the DBP, respectively. According to the Revised British Hypertension Society (BHS) protocol defining procedures for validation of BP monitors for special groups and in special circumstances (pregnant, children, elderly subjects, etc.), BP is required to be assessed in 30 subjects from the particular studied population and evaluated against a reference method (including ausculatory method). To achieve the highest degree of accuracy (grade A), the difference in BP values obtained by a tested method and a reference method must be ≤15 mm Hg in at least 95% of measurements, ≤10 mm Hg in at least 85%, and at least ≤5 mm Hg in at least 60% of measurements. 18 In categories, ≤15 mm Hg, ≤10 mm Hg, and ≤5 mm Hg, the ExpBP monitor achieved 99%, 93%, and 65% for SBP and 100%, 95%, and 57% for DBP. The existing standard of the International Organization for Standardization ISO 81060-2:2013 allows for BP monitors validation in groups with special conditions. The norm defines pass/fail criteria based on BP mean difference between tested and invasive reference method ≤5 mm Hg with SD ±8 mm Hg from all measurements (minimum of 150 measurement on 15 patients). 19 Further improvement of the accuracy using oscillometric principle in patients supported by CF LVAD may be challenging because of a diminished PP, where movement artifacts and particularly the low-frequency respiratory-synchronous BP modulation, have relatively higher impact on the recorded BP was assessed three times by each method for a total of 31 subjects resulting in 93 measurement attempts by each method. BP, blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; SBP, systolic blood pressure. signal compared with the non-LVAD population. This may generate a flatter oscillometric envelop (Figure 1) , which in turn increases the level of uncertainty in the detection of the maximal peak. In response, this may negatively affect the accuracy of MAP assessment, and consequently, also impact calculations of SBP and DBP. Paradoxically, artifacts traditionally perceived to be challenging for the oscillometric method in non-LVAD population (arrhythmias, mainly atrial fibrillation) may have smaller effect on the accuracy or measurement success rate in the LVAD population because of the position of the pump by-passing the left ventricle (LV). In this setting, the atrial contribution to the final stroke volume is diluted between the pump and the LV output, which may be seen in a relatively less pronounced beat-to-beat stroke volume variability during uneven LV filling. Our data suggest that the BP assessment should not be significantly affected when the residual PP exceeds approximately 5 mm Hg. This may have positive clinical implications also for the aortic valve closure post-LVAD implantation, surgical procedure performed in indicated cases to prevent progression of the aortic insufficiency.
LVAD-Specific Performance Assessment of the Experimental BP Monitor
Apart from the accuracy and reliability of BP assessment, a common problem of BP monitors not specifically designed for the patients supported by LVAD is a remarkable rate of error readings, when no BP value is provided by an automated monitor. 4, 5 In this study, the ExpBP monitor achieved more than 90% of successful BP readings for the second and third measurement attempts for MAP, SBP, and DBP (Table 3) , despite the majority of subjects receiving vasopressors at the time data collection. The success rates were maximized because of a unique feature to provide each of the BP values independently, even if the SBP or DBP was a missing value. Authors speculated that the ExpBP monitor might possibly achieve an even higher success rate in a stable CF LVAD population with a longer time post-LVAD implantation and no pharmacologically induced peripheral vasoconstriction. This needs to be confirmed in further studies.
Arterial PP and Pulsatility Index
Interpretations of calculated PP (PP = SBP − DBP) should be used with caution in potential attempts to use this information for the pump setting evaluation. The extrapolation of the value of pulsatility index (PI) provided by HeartMate pumps to the calculated PP remains challenging because no significant correlation was found between the ExpBP monitor PP and PI (r = 0.35; p = 0.15; n = 20) and also between the I-A PP and PI (r = 0.28; p = 0.23; n = 20) in the dataset collected on subjects very shortly after the LVAD placement. Hence, further effort is required in technological research focused on developing more reliable methods for a precise assessment of the residual pulsatility to enable its clinical utilization beyond the traditional PI value provided by the HM device controllers, as stressed by Cheng et al. 20 and Edwards et al. 21 Promising improvements in hemodynamic monitoring of patients supported by LVAD may be seen in future with clinical implementation of implantable hemodynamic sensors.
Overall, the current results suggest excellent performance of the ExpBP monitor in the assessment of SBP, DBP, and MAP compared with recently published data focused on testing monitors for BP measurement in the CF LVAD population. 5, 22 Present work is in consideration with the idea of implementing automated BP monitors suitable to patients with CF physiology into clinical practice. 23 
Accuracy of the Doppler BP in Respect to the Arterial PP and Clinical Implications
The Doppler technique achieved very high measurement success rate and repeatability, in concordance with published literature. 4, 5, 8 Although the Doppler BP showed strong correlation with the I-A MAP, overall Doppler overestimated I-A MAP in average by 6.7 (5.8) mm Hg ( Figure 3B ) and underestimated SBP by 5.0 (6.6) mm Hg. Furthermore, the data revealed a positive relationship between the I-A PP and the I-A MAP to Doppler BP difference (Figure 4, A and B) . This data supports previous observations by Lanier et al. 5 that the accuracy of MAP assessment by the Doppler technique decreases with increased pulsatility. Thus, in patients with a higher PP, the Doppler may determine more closely I-A SBP rather than I-A MAP. This relationship may have an important clinical implication in managing post-LVAD hypertension based on the recommendation to maintain the Doppler BP between 70 and 80 mm Hg and not to exceed 90 mm Hg. [24] [25] [26] Thus, with increased pulsatility, there is a risk of overdosing antihypertensive therapy because of significantly higher differences between the true MAP versus the measured Doppler BP. In turn, potential chronic hypoperfusion may contribute to impaired glomerular filtration pressure, increasing risk of orthostatic hypotension with syncope and higher risk of cranial trauma. Other than the inability to provide SBP and DBP, the limitation of the Doppler technique is in the need for a trained person to perform a measurement. Yet, despite the clinical importance, this limitation of the Doppler technique will remain unsolved until either another physiologic surrogate for the peripheral arterial pulsatility assessment will be implemented in the Doppler technique or until an LVADspecific automated BP monitors will overcome the limitations of the Doppler to provide only a single BP value. However, the remarkable success rate of Doppler technique may reserve a continuing position of this technique in the setting of hemodynamically challenging conditions (e.g., circulatory shock).
Study Limitations
In the current study, we tested the performance of the ExpBP monitor prototype. For clinical use, the final design of the monitor will require extended clinical validation. The BHS validation protocol requires specific distribution of BP values in the tested population, which was not appreciated in current study. 18 Because the ExpBP monitor was tested on critically ill subjects, the methodology was limited by certain inconsistency in noninvasive BP measurements being acquired on either ipsilateral or contralateral arm from the reference method (because of vein thrombosis, etc.). However, none of the subjects included in the study were to be found with a significant lateral BP difference. Moreover, although the BHS protocol does not recommend the BP to be assessed on the contralateral arm, the newer internationally valid ISO standard 81060-2 allows this approach after the lateral difference determination. 18, 19 Finally, the results from the Doppler technique could be positively or negatively biased, because the Doppler BP assessment was not blinded from the invasive BP.
Conclusions
The ExpBP monitor was able to assess SBP, DBP, and MAP in the majority of CF LVAD subjects supported either by axial or centrifugal pumps with good agreement to the I-A BP. The independent displaying SBP and DBP after MAP determination may improve overall measurement success rates. Automated BP monitors specifically designed for the patients supported by CF LVAD might simplify self-and home monitoring of BP, contribute to safer use of antihypertensive drugs, and, in turn, may alleviate adverse outcomes associated with poor BP control.
